Streetbeat News

GRNA

GreenLight Biosciences Holdings PBC

Employees

298

Industry

Research and Development in Biotechnology

greenlight biosciences is a privately-held biotechnology company focused on sustainable production of chemicals and fuels using its patented cell free bioprocessing technology platform. this revolutionary technology enables the biological conversion of economical, renewable substrates to valuable products with unprecedented flexibility and control.

Open

0.30

Mkt cap

45M

Volume

143K

High

0.30

P/E Ratio

-0.27

52-wk high

5.90

Low

0.30

Div yield

N/A

52-wk low

0.18

GreenLight Biosciences Holdings (NASDAQ:GRNA) is finalizing its merger with SW MergerCo, Inc. and SW ParentCo, Inc. Post-merger, GreenLight's common stock will cease trading on the NASDAQ after market close on July 20, 2023. The tender offer for GreenLight's outstanding shares expired on July 19, 2023, with approximately 60.4% of the shares validly tendered. Remaining shares not purchased in the offer will be converted into the right to receive $0.30 in cash.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 12:13 pm

Canaccord Genuity analyst Bobby Burleson downgrades GreenLight Biosciences (NASDAQ:GRNA) from Buy to Hold and lowers the price target from $4 to $0.3.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 12:31 pm

Nvidia shares are trading higher by over 5% after the company announced it would build the Israel-1 generative AI cloud supercomputer. Other stocks moving in Tuesday's mid-day session include QualTek Services, T2 Biosystems, Aclarion, Arlington Asset Investment Corp, and GreenLight Biosciences Holdings.

Portfolio Pulse from Lisa Levin

May 30, 2023 | 5:27 pm

GreenLight Biosciences is set to be acquired by a group of buyers led by Fall Line Capital in an all-cash transaction valuing the company at approximately $45.5 million.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 1:33 pm

GreenLight Biosciences shares have resumed trading after a temporary halt. The company is known for its RNA-based solutions for agriculture, human health, and animal health.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 11:31 am

GreenLight Biosciences shares will resume trading at 7:30 AM ET.

Portfolio Pulse from Charles Gross

May 30, 2023 | 11:12 am

GreenLight Biosciences has entered into an agreement to be acquired by a consortium led by Fall Line Endurance Fund in an all-cash transaction valued at $45.5 million.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 11:03 am

Greenlight Biosciences' trading has been halted pending news. The company is listed under the symbol GRNA.

Portfolio Pulse from Charles Gross

May 30, 2023 | 10:59 am

On Monday, 85 stocks hit new 52-week lows, with Bristol-Myers Squibb being the biggest company on a market cap basis to set a new low. Adamis Pharmaceuticals was the biggest loser, trading down 6320.0%, while Greystone Housing Impact shares were the most resilient, rising 0.0%.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 4:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.